Crinetics Pharmaceuticals (CRNX) Misses Q1 EPS by 13c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q1 EPS of ($0.93), $0.13 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $600 thousand versus the consensus estimate of $111.11 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Wolfe upgrades AT&T to Outperform as improving fundamentals outweigh Starlink risk
• Origin Bancorp, Inc. (OBK) Tops Q2 EPS by 9c
• Kearny Financial (KRNY) Misses Q4 EPS by 2c